AI Article Synopsis
- - The study investigated the role of interleukin (IL)-38 in vitiligo, an autoimmune disorder leading to skin depigmentation, comparing serum levels in 21 patients to 21 healthy controls (Hcs).
- - Results showed that vitiligo patients had significantly elevated IL-38 levels, particularly those with active symptoms, and there were positive correlations with disease severity and negative correlations with patient age and age at disease onset.
- - The findings suggest that IL-38 levels could be an important marker for assessing vitiligo severity and activity, indicating a potential role in the disease mechanism.
Article Abstract
Background: Vitiligo is an acquired cutaneous depigmenting disease caused by a T helper (Th) 1-cytotoxic T cells driven autoimmune attack against melanocytes, in which Th17 is also involved. Interleukin (IL)-38 belongs to the IL-1 family of cytokines and suppresses Th1 and Th17 activation. IL-38 protein and mRNA levels have been found to be elevated in various autoimmune disorders and correlated with disease severity and activity, including psoriasis, systemic sclerosis, rheumatoid arthritis, and atopic dermatitis. No previous studies have been performed to investigate the expression of IL-38 in patients with vitiligo.
Aim: To evaluate IL-38 serum level in patients with vitiligo compared to healthy controls (Hcs) and examine the association between IL-38 level and severity and activity of vitiligo.
Patients And Methods: The study comprised 21 patients with vitiligo and 21 Hcs. Vitiligo severity and activity were evaluated via Vitiligo Extent Score (VES) and Vitiligo Disease Activity (VIDA) Score, respectively. IL-38 serum level was evaluated by enzyme-linked immunosorbent assay.
Results: Vitiligo patients had significantly higher serum level of IL-38 than Hcs (p < 0.001). This level was significantly higher among patients with signs of vitiligo activity (p = 0.048), correlated positively with VES (p < 0.001), and correlated negatively with the age of patients (p = 0.001) and the age of disease onset (p = 0.022).
Conclusion: IL-38 serum level was higher in patients with vitiligo than in Hcs and was related to vitiligo severity and signs of activity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jocd.14612 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recent trends in the treatment of vitiligo using novel drug delivery system.
Int J Pharm
December 2024
Department of Pharmacology, Rungta College of Pharmaceutical Sciences and Research, Bhilai, Chhattisgarh 490024, India.
Vitiligo is a complex dermatological disorder involving the loss of melanocytes, with resultant patches of depigmentation. It affects 1% of the world population, affecting patients' mental health and quality of life. With all the improvement seen, conventional treatment methods-steroids, phototherapy, and immunomodulators-come with the limitations of being less effective, having more side effects, and low compliance.
View Article and Find Full Text PDFImmune Checkpoint Inhibitor-Induced Vitiligo-Like Depigmentation.
JAMA Dermatol
December 2024
Oncodermatology Department, Institut Universitaire du Cancer, Toulouse Oncopole, Toulouse, France.
Efficacy and Safety of Janus Kinase Inhibitors in Patients with Vitiligo: A Systematic Review and Meta-Analysis.
Clin Pharmacol Ther
December 2024
Clinical Trial Institution, Peking University People's Hospital, Beijing, China.
Although several case reports and small clinical trials have reported promising outcomes with Janus kinase (JAK) inhibitors for vitiligo, high-quality evidence and guidelines are lacking. We evaluated the efficacy and safety of JAK inhibitors for the treatment of vitiligo using a meta-analysis of randomized controlled trials (RCTs). We searched the PubMed, Embase, and Cochrane Library databases up to August 2023, with additional studies from ClinicalTrials.
View Article and Find Full Text PDFVitiligo: Clinical and Laboratory Characteristics in 573 Saudi Patients.
Clin Cosmet Investig Dermatol
December 2024
Division of Dermatology, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Background: Vitiligo is a common disease. Limited studies in Saudi Arabia have explored the detailed clinical characteristics of vitiligo, as outlined in recent consensus reports by vitiligo experts.
Objective: To determine vitiligo prevalence and detailed clinical characteristics in a Saudi cohort.
Response to ritlecitinib with or without narrow-band UVB add-on therapy in patients with active nonsegmental vitiligo: results from a phase 2b extension study.
J Am Acad Dermatol
December 2024
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address:
Background: Ritlecitinib demonstrated efficacy in a phase 2b trial of nonsegmental vitiligo.
Objective: To evaluate the efficacy and tolerability of ritlecitinib with add-on narrow-band UVB (nbUVB) phototherapy in patients with nonsegmental vitiligo.
Methods: Following a 24-week, placebo-controlled, dose-ranging period, patients received ritlecitinib 200mg for 4 weeks then 50mg for 20 weeks, with or without nbUVB phototherapy 2x/week.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!